Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Fiddian-Green
Richard G
RG
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D016207:Cytokines / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D004731:Endotoxins / Q000378:metabolism; D004734:Energy Metabolism; D005753:Gastric Mucosa / Q000378:metabolism / Q000382:microbiology / Q000503:physiopathology; D016481:Helicobacter Infections / Q000209:etiology* / Q000378:metabolism* / Q000517:prevention & control; D016480:Helicobacter pylori / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism / Q000382:microbiology / Q000503:physiopathology; D007980:Levodopa / Q000009:adverse effects / Q000493:pharmacokinetics*; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*
D000978:Antiparkinson Agents; D016207:Cytokines; D004731:Endotoxins; D007980:Levodopa